Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification

Keyphrases

• Immune Checkpoint Inhibitors 100%
• Acute Pancreatitis 100%
• Proposal Classification 100%
• Pancreatic Involvement 100%
• Nivolumab 75%
• Pancreatic Injury 75%
• Immune Checkpoint Inhibitor Therapy 75%
• Pancreatic Atrophy 75%
• Immune-related Adverse Events 50%
• Revised Atlanta Classification 50%
• Retrospective Cohort Study 25%
• Cancer Patients 25%
• Diagnostic Criteria 25%
• Pancreas 25%
• Common Terminology Criteria for Adverse Events (CTCAE) 25%
• Programmed Death-ligand 1 (PD-L1) 25%
• Selection Criteria 25%
• Difference in Mean 25%
• Treatment Decisions 25%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 25%
• National Cancer Institute Common Terminology Criteria for Adverse Events 25%
• Novel Classification 25%
• PD-1 Inhibitor 25%
• Pembrolizumab 25%
• Exocrine Pancreatic Insufficiency 25%
• Event Definition 25%
• Mild Acute Pancreatitis 25%
• Drug-induced Pancreatitis 25%

Medicine and Dentistry

• Immune Checkpoint Inhibitor 100%
• Acute Pancreatitis 100%
• Nivolumab 60%
• Pancreatic Injury 60%
• Malignant Neoplasm 40%
• Adverse Event 40%
• Immune-Related Adverse Events 40%
• Retrospective Cohort Study 20%
• Cytotoxic T-Cell 20%
• Programmed Death 1 Receptor 20%
• Pembrolizumab 20%
• Exocrine Pancreatic Insufficiency 20%
• Drug Induced Acute Pancreatitis 20%
• Diagnostic Criterion 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Pancreatitis 100%
• Immune Checkpoint Inhibitor 100%
• Adverse Event 66%
• Nivolumab 50%
• Pancreas Injury 50%
• Malignant Neoplasm 33%
• Cohort Study 16%
• Programmed Death 1 Receptor 16%
• Pembrolizumab 16%
• Exocrine Pancreatic Insufficiency 16%